Cardiol Therapeutics Inc. 6-K filed 2026-09-11

Cardiol Therapeutics Inc. filed a Form 6-K with the SEC on 2026-09-11. The excerpt shows that the filing includes an Exclusive Master Services Agreement between Cardiol Therapeutics Inc. and Dalton Chemical Laboratories, Inc., operating as Dalton Pharma Services, a contractor incorporated in Ontario, Canada. Some information in the document has been redacted for personal privacy reasons and is marked with [***]. Cardiol trades on Nasdaq under the ticker CRDL, is classified under Biological Products, (No Diagnostic Substances), and is listed as an Emerging growth company. In the agreement, Cardiol describes itself as a healthcare company working on the research, development, sales, and marketing of therapies for human diseases. Dalton is described as a contract services company that works on pharmaceutical discovery, development, formulation, synthesis, manufacturing, filling, and analysis. Services under the agreement include manufacturing the API, its intermediates or derivatives, and products that contain them, as well as developing manufacturing processes. The Territory is defined as the world. For an analyst or journalist, the key point is exclusivity. Dalton agrees to provide Services in the Field only to Cardiol. It also agrees not to supply Services, Product, Work Product, or intellectual property rights in the Field to any third party, and not to commercialize them itself. In exchange, Cardiol agrees to allot and issue shares in the company to Dalton. The excerpt stops at that point, so the number of shares, their value, and any other terms of the consideration are not in the excerpt. Several other details are also not in the excerpt. These include the definition of the API in Appendix A, pricing and payment terms, the term and termination provisions, and the reason Cardiol filed the agreement now. The full document is available at the source link.